Predicting substrates of the human breast cancer resistance protein using a support vector machine method

BackgroundHuman breast cancer resistance protein (BCRP) is an ATP-binding cassette (ABC) efflux transporter that confers multidrug resistance in cancers and also plays an important role in the absorption, distribution and elimination of drugs. Prediction as to if drugs or new molecular entities are BCRP substrates should afford a cost-effective means that can help evaluate the pharmacokinetic properties, efficacy, and safety of these drugs or drug candidates. At present, limited studies have been done to develop in silico prediction models for BCRP substrates.In this study, we developed support vector machine (SVM) models to predict wild-type BCRP substrates based on a total of 263 known BCRP substrates and non-substrates collected from literature. The final SVM model was integrated to a free web server.ResultsWe showed that the final SVM model had an overall prediction accuracy of ~73% for an independent external validation data set of 40 compounds. The prediction accuracy for wild-type BCRP substrates was ~76%, which is higher than that for non-substrates. The free web server (http://bcrp.althotas.com) allows the users to predict whether a query compound is a wild-type BCRP substrate and calculate its physicochemical properties such as molecular weight, logP value, and polarizability.ConclusionsWe have developed an SVM prediction model for wild-type BCRP substrates based on a relatively large number of known wild-type BCRP substrates and non-substrates. This model may prove valuable for screening substrates and non-substrates of BCRP, a clinically important ABC efflux drug transporter.

[1]  M. D. Boer,et al.  Multidrug resistance genes in infant acute lymphoblastic leukemia: Ara-C is not a substrate for the breast cancer resistance protein , 2004, Leukemia.

[2]  A. V. van Herwaarden,et al.  Breast cancer resistance protein (Bcrp1/Abcg2) reduces systemic exposure of the dietary carcinogens aflatoxin B1, IQ and Trp-P-1 but also mediates their secretion into breast milk. , 2006, Carcinogenesis.

[3]  Y. Sugimoto,et al.  Phytoestrogens/Flavonoids Reverse Breast Cancer Resistance Protein/ABCG2-Mediated Multidrug Resistance , 2004, Cancer Research.

[4]  Jos H Beijnen,et al.  P-Glycoprotein (ABCB1) and Breast Cancer Resistance Protein (ABCG2) Restrict Brain Accumulation of the Active Sunitinib Metabolite N-Desethyl Sunitinib , 2012, Journal of Pharmacology and Experimental Therapeutics.

[5]  Stephan Kopp,et al.  Multispecificity of Drug Transporters: Probing Inhibitor Selectivity for the Human Drug Efflux Transporters ABCB1 and ABCG2 , 2007, ChemMedChem.

[6]  Y. Sugimoto,et al.  Single amino acid substitutions in the transmembrane domains of breast cancer resistance protein (BCRP) alter cross resistance patterns in transfectants , 2003, International journal of cancer.

[7]  Kazuya Maeda,et al.  Identification of the Hepatic Efflux Transporters of Organic Anions Using Double-Transfected Madin-Darby Canine Kidney II Cells Expressing Human Organic Anion-Transporting Polypeptide 1B1 (OATP1B1)/Multidrug Resistance-Associated Protein 2, OATP1B1/Multidrug Resistance 1, and OATP1B1/Breast Cancer R , 2005, Journal of Pharmacology and Experimental Therapeutics.

[8]  F H Hausheer,et al.  Circumvention of breast cancer resistance protein (BCRP)-mediated resistance to camptothecins in vitro using non-substrate drugs or the BCRP inhibitor GF120918. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[9]  Yuichi Sugiyama,et al.  Lack of Improvement of Oral Absorption of ME3277 by Prodrug Formation Is Ascribed to the Intestinal Efflux Mediated by Breast Cancer Resistant Protein (BCRP/ABCG2) , 2005, Pharmaceutical Research.

[10]  Gary Williamson,et al.  Predicting Phenolic Acid Absorption in Caco-2 Cells: A Theoretical Permeability Model and Mechanistic Study , 2012, Drug Metabolism and Disposition.

[11]  D. Voelker,et al.  Glutathione Transport Is a Unique Function of the ATP-binding Cassette Protein ABCG2* , 2010, The Journal of Biological Chemistry.

[12]  Hikaru Saito,et al.  Molecular modeling of new camptothecin analogues to circumvent ABCG2-mediated drug resistance in cancer. , 2006, Cancer letters.

[13]  Ulf Norinder,et al.  A Global Drug Inhibition Pattern for the Human ATP-Binding Cassette Transporter Breast Cancer Resistance Protein (ABCG2) , 2007, Journal of Pharmacology and Experimental Therapeutics.

[14]  Honggang Wang,et al.  The Breast Cancer Resistance Protein (Bcrp1/Abcg2) Limits Fetal Distribution of Glyburide in the Pregnant Mouse: An Obstetric-Fetal Pharmacology Research Unit Network and University of Washington Specialized Center of Research Study , 2007, Molecular Pharmacology.

[15]  Baojian Wu,et al.  UDP-Glucuronosyltransferase (UGT) 1A9-Overexpressing HeLa Cells Is an Appropriate Tool to Delineate the Kinetic Interplay between Breast Cancer Resistance Protein (BRCP) and UGT and to Rapidly Identify the Glucuronide Substrates of BCRP , 2012, Drug Metabolism and Disposition.

[16]  A. Schinkel,et al.  TRANSPORT OF ANTHELMINTIC BENZIMIDAZOLE DRUGS BY BREAST CANCER RESISTANCE PROTEIN (BCRP/ABCG2) , 2005, Drug Metabolism and Disposition.

[17]  Yi Zhang,et al.  HIV Protease Inhibitors Are Inhibitors but Not Substrates of the Human Breast Cancer Resistance Protein (BCRP/ABCG2) , 2004, Journal of Pharmacology and Experimental Therapeutics.

[18]  T Ishikawa,et al.  Quantitative structure-activity relationship (QSAR) analysis to predict drug-drug interactions of ABC transporter ABCG2. , 2012, Mini reviews in medicinal chemistry.

[19]  Li Li,et al.  pH-Dependent Transport of Pemetrexed by Breast Cancer Resistance Protein , 2011, Drug Metabolism and Disposition.

[20]  Nicolas Tournier,et al.  Interaction of drugs of abuse and maintenance treatments with human P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2). , 2010, The international journal of neuropsychopharmacology.

[21]  Nicolas Tournier,et al.  Transport of Selected PET Radiotracers by Human P-Glycoprotein (ABCB1) and Breast Cancer Resistance Protein (ABCG2): An In Vitro Screening , 2011, The Journal of Nuclear Medicine.

[22]  Giancarlo Albo,et al.  Bicalutamide failure in prostate cancer treatment: involvement of Multi Drug Resistance proteins. , 2008, European journal of pharmacology.

[23]  B. Torok-Storb,et al.  The ABCG2 transporter is an efficient Hoechst 33342 efflux pump and is preferentially expressed by immature human hematopoietic progenitors. , 2002, Blood.

[24]  P. Carrupt,et al.  QSAR analysis and molecular modeling of ABCG2-specific inhibitors. , 2009, Advanced drug delivery reviews.

[25]  Jos H. Beijnen,et al.  Breast Cancer Resistance Protein and P-glycoprotein Limit Sorafenib Brain Accumulation , 2010, Molecular Cancer Therapeutics.

[26]  Francesca Borrelli,et al.  Nonprenylated rotenoids, a new class of potent breast cancer resistance protein inhibitors. , 2007, Journal of medicinal chemistry.

[27]  Yuichi Sugiyama,et al.  Evaluation of the Role of Breast Cancer Resistance Protein (BCRP/ABCG2) and Multidrug Resistance-Associated Protein 4 (MRP4/ABCC4) in The Urinary Excretion of Sulfate and Glucuronide Metabolites of Edaravone (MCI-186; 3-Methyl-1-phenyl-2-pyrazolin-5-one) , 2007, Drug Metabolism and Disposition.

[28]  Yves Pommier,et al.  ABCG2 Mediates Differential Resistance to SN-38 (7-Ethyl-10-hydroxycamptothecin) and Homocamptothecins , 2004, Journal of Pharmacology and Experimental Therapeutics.

[29]  G. Merino,et al.  Interaction of enrofloxacin with breast cancer resistance protein (BCRP/ABCG2): influence of flavonoids and role in milk secretion in sheep. , 2006, Journal of veterinary pharmacology and therapeutics.

[30]  S. Balleydier,et al.  Transepithelial transport of fusariotoxin nivalenol: mediation of secretion by ABC transporters. , 2007, Toxicology letters.

[31]  Jos H. Beijnen,et al.  Brain Accumulation of Dasatinib Is Restricted by P-Glycoprotein (ABCB1) and Breast Cancer Resistance Protein (ABCG2) and Can Be Enhanced by Elacridar Treatment , 2009, Clinical Cancer Research.

[32]  F. Meng,et al.  A novel class of tubulin inhibitors that exhibit potent antiproliferation and in vitro vessel-disrupting activity , 2008, Cancer Chemotherapy and Pharmacology.

[33]  S. Bates,et al.  Differential effects of the breast cancer resistance protein on the cellular accumulation and cytotoxicity of 9-aminocamptothecin and 9-nitrocamptothecin. , 2003, Cancer research.

[34]  H. Rosing,et al.  The breast cancer resistance protein protects against a major chlorophyll-derived dietary phototoxin and protoporphyria , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[35]  Yong-Hae Han,et al.  Involvement of P-glycoprotein, Multidrug Resistance Protein 2 and Breast Cancer Resistance Protein in the Transport of Belotecan and Topotecan in Caco-2 and MDCKII Cells , 2008, Pharmaceutical Research.

[36]  J. Espín,et al.  Bioavailability of the Glucuronide and Sulfate Conjugates of Genistein and Daidzein in Breast Cancer Resistance Protein 1 Knockout Mice , 2011, Drug Metabolism and Disposition.

[37]  Yehuda G. Assaraf,et al.  Mutant Gly482 and Thr482 ABCG2 mediate high-level resistance to lipophilic antifolates , 2006, Cancer Chemotherapy and Pharmacology.

[38]  R. Rosales,et al.  Characterization of the Role of ABCG2 as a Bile Acid Transporter in Liver and Placenta , 2012, Molecular Pharmacology.

[39]  Jeffrey C Stevens,et al.  Preclinical and Clinical Evidence for the Collaborative Transport and Renal Secretion of an Oxazolidinone Antibiotic by Organic Anion Transporter 3 (OAT3/SLC22A8) and Multidrug and Toxin Extrusion Protein 1 (MATE1/SLC47A1) , 2010, Journal of Pharmacology and Experimental Therapeutics.

[40]  Alfonso Lampen,et al.  Identification of BCRP as transporter of benzo[a]pyrene conjugates metabolically formed in Caco-2 cells and its induction by Ah-receptor agonists. , 2005, Carcinogenesis.

[41]  Jos H. Beijnen,et al.  In vitro transport of gimatecan (7-t-butoxyiminomethylcamptothecin) by breast cancer resistance protein, P-glycoprotein, and multidrug resistance protein 2 , 2007, Molecular Cancer Therapeutics.

[42]  Yang Dai,et al.  Cyclosporin A, tacrolimus and sirolimus are potent inhibitors of the human breast cancer resistance protein (ABCG2) and reverse resistance to mitoxantrone and topotecan , 2006, Cancer Chemotherapy and Pharmacology.

[43]  Suneet Shukla,et al.  The naphthoquinones, vitamin K3 and its structural analogue plumbagin, are substrates of the multidrug resistance–linked ATP binding cassette drug transporter ABCG2 , 2007, Molecular Cancer Therapeutics.

[44]  G. Hankins,et al.  Role of transporter-mediated efflux in the placental biodisposition of bupropion and its metabolite, OH-bupropion. , 2010, Biochemical pharmacology.

[45]  J. Allen,et al.  Inhibition of BCRP-mediated drug efflux by fumitremorgin-type indolyl diketopiperazines. , 2001, Bioorganic & medicinal chemistry letters.

[46]  Eszter Hazai,et al.  Predicting P-Glycoprotein-Mediated Drug Transport Based On Support Vector Machine and Three-Dimensional Crystal Structure of P-glycoprotein , 2011, PloS one.

[47]  T. Litman,et al.  Acquired mutations in the MXR/BCRP/ABCP gene alter substrate specificity in MXR/BCRP/ABCP-overexpressing cells. , 2001, Cancer research.

[48]  F. Lee,et al.  Ixabepilone, a Novel Microtubule-Targeting Agent for Breast Cancer, Is a Substrate for P-Glycoprotein (P-gp/MDR1/ABCB1) but not Breast Cancer Resistance Protein (BCRP/ABCG2) , 2011, Journal of Pharmacology and Experimental Therapeutics.

[49]  Gilbert Bensimon,et al.  Interactions between riluzole and ABCG2/BCRP transporter , 2009, Neuroscience Letters.

[50]  Yiyu Cheng,et al.  Identifying P-Glycoprotein Substrates Using a Support Vector Machine Optimized by a Particle Swarm , 2007, J. Chem. Inf. Model..

[51]  S. Bates,et al.  Mutations at amino-acid 482 in the ABCG2 gene affect substrate and antagonist specificity , 2003, British Journal of Cancer.

[52]  S. Bates,et al.  Pheophorbide a Is a Specific Probe for ABCG2 Function and Inhibition , 2004, Cancer Research.

[53]  Atsushi Ose,et al.  Quantitative Investigation of the Role of Breast Cancer Resistance Protein (Bcrp/Abcg2) in Limiting Brain and Testis Penetration of Xenobiotic Compounds , 2008, Drug Metabolism and Disposition.

[54]  J. F. Wang,et al.  Prediction of P-Glycoprotein Substrates by a Support Vector Machine Approach , 2004, J. Chem. Inf. Model..

[55]  Mariël Brok,et al.  Imatinib mesylate (STI571) is a substrate for the breast cancer resistance protein (BCRP)/ABCG2 drug pump. , 2004, Blood.

[56]  Kelly H. Jordan,et al.  The systemic exposure of an N-methyl-D-aspartate receptor antagonist is limited in mice by the P-glycoprotein and breast cancer resistance protein efflux transporters. , 2004, Drug metabolism and disposition: the biological fate of chemicals.

[57]  Massimo Zucchetti,et al.  Tyrosine kinase inhibitors and multidrug resistance proteins: interactions and biological consequences , 2009, Cancer Chemotherapy and Pharmacology.

[58]  Yuichi Sugiyama,et al.  ABCG2 Transports Sulfated Conjugates of Steroids and Xenobiotics* , 2003, Journal of Biological Chemistry.

[59]  Jos H Beijnen,et al.  Differential Impact of P-Glycoprotein (ABCB1) and Breast Cancer Resistance Protein (ABCG2) on Axitinib Brain Accumulation and Oral Plasma Pharmacokinetics , 2011, Drug Metabolism and Disposition.

[60]  Yuichi Sugiyama,et al.  Effect of Breast Cancer Resistance Protein (Bcrp/Abcg2) on the Disposition of Phytoestrogens , 2007, Molecular Pharmacology.

[61]  A. Sparreboom,et al.  Effect of ABCC2 (MRP2) Transport Function on Erythromycin Metabolism , 2011, Clinical pharmacology and therapeutics.

[62]  Yuichi Sugiyama,et al.  Involvement of Breast Cancer Resistance Protein (BCRP/ABCG2) in the Biliary Excretion and Intestinal Efflux of Troglitazone Sulfate, the Major Metabolite of Troglitazone with a Cholestatic Effect , 2007, Drug Metabolism and Disposition.

[63]  Xin Wang,et al.  Breast cancer resistance protein (BCRP/ABCG2) induces cellular resistance to HIV-1 nucleoside reverse transcriptase inhibitors. , 2003, Molecular pharmacology.

[64]  Gideon Koren,et al.  Acyclovir is a substrate for the human breast cancer resistance protein (BCRP/ABCG2): implications for renal tubular transport and acyclovir-induced nephrotoxicity. , 2011, Canadian journal of physiology and pharmacology.

[65]  K. Német,et al.  Leflunomide and its metabolite A771726 are high affinity substrates of BCRP: implications for drug resistance , 2008, Annals of the rheumatic diseases.

[66]  Suneet Shukla,et al.  Synthesis and characterization of a BODIPY conjugate of the BCR-ABL kinase inhibitor Tasigna (nilotinib): evidence for transport of Tasigna and its fluorescent derivative by ABC drug transporters. , 2011, Molecular pharmaceutics.

[67]  Marilyn E. Morris,et al.  Structure–Activity Relationships and Quantitative Structure–Activity Relationships for Breast Cancer Resistance Protein (ABCG2) , 2009, The AAPS Journal.

[68]  Xin Wang,et al.  Induction of cellular resistance to nucleoside reverse transcriptase inhibitors by the wild-type breast cancer resistance protein. , 2004, Biochemical pharmacology.

[69]  Jos H Beijnen,et al.  Multidrug resistance protein 2 (MRP2) transports HIV protease inhibitors, and transport can be enhanced by other drugs , 2002, AIDS.

[70]  H. Kotani,et al.  Identification of breast cancer resistant protein/mitoxantrone resistance/placenta-specific, ATP-binding cassette transporter as a transporter of NB-506 and J-107088, topoisomerase I inhibitors with an indolocarbazole structure. , 2001, Cancer research.

[71]  Balázs Sarkadi,et al.  Single amino acid (482) variants of the ABCG2 multidrug transporter: major differences in transport capacity and substrate recognition. , 2005, Biochimica et biophysica acta.

[72]  M R Baer,et al.  Amonafide L-malate is not a substrate for multidrug resistance proteins in secondary acute myeloid leukemia , 2008, Leukemia.

[73]  Gajendra PS Raghava,et al.  RESEARCH ARTICLE Open Access Research article Prediction of cytochrome P450 isoform responsible , 2022 .

[74]  H. Rosing,et al.  Multidrug Transporter ABCG2/Breast Cancer Resistance Protein Secretes Riboflavin (Vitamin B2) into Milk , 2006, Molecular and Cellular Biology.

[75]  Piet Borst,et al.  Contribution of the drug transporter ABCG2 (breast cancer resistance protein) to resistance against anticancer nucleosides , 2008, Molecular Cancer Therapeutics.

[76]  S. Nishimura,et al.  ABCG2 confers resistance to indolocarbazole compounds by ATP-dependent transport. , 2002, Biochemical and biophysical research communications.

[77]  P. Pávek,et al.  Lack of Interactions between Breast Cancer Resistance Protein (BCRP/ABCG2) and Selected Antiepileptic Agents , 2006, Epilepsia.

[78]  D. Ross,et al.  Role of breast cancer resistance protein (BCRP/ABCG2) in cancer drug resistance. , 2012, Biochemical pharmacology.

[79]  Yuichi Sugiyama,et al.  Involvement of Breast Cancer Resistance Protein (ABCG2) in the Biliary Excretion Mechanism of Fluoroquinolones , 2007, Drug Metabolism and Disposition.

[80]  Marilyn E Morris,et al.  The Bioflavonoid Kaempferol Is an Abcg2 Substrate and Inhibits Abcg2-Mediated Quercetin Efflux , 2011, Drug Metabolism and Disposition.

[81]  Kazuya Maeda,et al.  Multiple Human Isoforms of Drug Transporters Contribute to the Hepatic and Renal Transport of Olmesartan, a Selective Antagonist of the Angiotensin II AT1-Receptor , 2007, Drug Metabolism and Disposition.

[82]  S. Vaidhyanathan,et al.  Impact of P-Glycoprotein (ABCB1) and Breast Cancer Resistance Protein (ABCG2) on the Brain Distribution of a Novel BRAF Inhibitor: Vemurafenib (PLX4032) , 2012, Journal of Pharmacology and Experimental Therapeutics.

[83]  J. Schellens,et al.  Mechanism of the Pharmacokinetic Interaction between Methotrexate and Benzimidazoles , 2004, Cancer Research.

[84]  Yehuda G Assaraf,et al.  Structural Determinants of Imidazoacridinones Facilitating Antitumor Activity Are Crucial for Substrate Recognition by ABCG2 , 2009, Molecular Pharmacology.

[85]  Kim L R Brouwer,et al.  The Important Role of Bcrp (Abcg2) in the Biliary Excretion of Sulfate and Glucuronide Metabolites of Acetaminophen, 4-Methylumbelliferone, and Harmol in Mice , 2006, Molecular Pharmacology.

[86]  Qingcheng Mao,et al.  Structure and function of the human breast cancer resistance protein (BCRP/ABCG2). , 2010, Current drug metabolism.

[87]  Pedro Gonçalves,et al.  The short-chain fatty acid butyrate is a substrate of breast cancer resistance protein. , 2011, American journal of physiology. Cell physiology.

[88]  Yan Ji,et al.  Membrane transport of dietary phenethyl isothiocyanate by ABCG2 (breast cancer resistance protein). , 2005, Molecular pharmaceutics.

[89]  Weiwei Hu,et al.  Side populations of glioblastoma cells are less sensitive to HSV-TK/GCV suicide gene therapy system than the non-side population , 2010, In Vitro Cellular & Developmental Biology - Animal.

[90]  Andreas Bender,et al.  P-glycoprotein Substrate Models Using Support Vector Machines Based on a Comprehensive Data set , 2011, J. Chem. Inf. Model..

[91]  M. Pomper,et al.  ABCG2/BCRP expression modulates D-Luciferin based bioluminescence imaging. , 2007, Cancer research.

[92]  Daxi Sun,et al.  Substrate overlap between Mrp4 and Abcg2/Bcrp affects purine analogue drug cytotoxicity and tissue distribution. , 2007, Cancer research.

[93]  E. Hudson,et al.  The multidrug-resistant phenotype associated with overexpression of the new ABC half-transporter, MXR (ABCG2). , 2000, Journal of cell science.

[94]  V. Soto-Cerrato,et al.  Mitochondria-mediated apoptosis operating irrespective of multidrug resistance in breast cancer cells by the anticancer agent prodigiosin. , 2004, Biochemical pharmacology.

[95]  O. Ogawa,et al.  ABCG2 421C>A polymorphism and high exposure of sunitinib in a patient with renal cell carcinoma. , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

[96]  Jos H. Beijnen,et al.  The Effect of Low pH on Breast Cancer Resistance Protein (ABCG2)-Mediated Transport of Methotrexate, 7-Hydroxymethotrexate, Methotrexate Diglutamate, Folic Acid, Mitoxantrone, Topotecan, and Resveratrol in In Vitro Drug Transport Models , 2007, Molecular Pharmacology.

[97]  Fan Zhang,et al.  MDM2 antagonist nutlin-3a reverses mitoxantrone resistance by inhibiting breast cancer resistance protein mediated drug transport. , 2011, Biochemical pharmacology.

[98]  Michael Wiese,et al.  Structure-activity relationships of new inhibitors of breast cancer resistance protein (ABCG2). , 2008, Bioorganic & medicinal chemistry.

[99]  Michael Dean,et al.  The livestock photosensitizer, phytoporphyrin (phylloerythrin), is a substrate of the ATP-binding cassette transporter ABCG2. , 2006, Research in veterinary science.

[100]  S. Rabindran,et al.  Reversal of a novel multidrug resistance mechanism in human colon carcinoma cells by fumitremorgin C. , 1998, Cancer research.

[101]  Francisco Gamarro,et al.  Flavonoid structure-activity studies identify 6-prenylchrysin and tectochrysin as potent and specific inhibitors of breast cancer resistance protein ABCG2. , 2005, Cancer research.

[102]  Jos H Beijnen,et al.  Transport of Diclofenac by Breast Cancer Resistance Protein (ABCG2) and Stimulation of Multidrug Resistance Protein 2 (ABCC2)-Mediated Drug Transport by Diclofenac and Benzbromarone , 2009, Drug Metabolism and Disposition.

[103]  Alfred H. Schinkel,et al.  Human Breast Cancer Resistance Protein: Interactions with Steroid Drugs, Hormones, the Dietary Carcinogen 2-Amino-1-methyl-6-phenylimidazo(4,5-b)pyridine, and Transport of Cimetidine , 2005, Journal of Pharmacology and Experimental Therapeutics.

[104]  Shuzhong Zhang,et al.  Structure activity relationships and quantitative structure activity relationships for the flavonoid-mediated inhibition of breast cancer resistance protein. , 2005, Biochemical pharmacology.

[105]  M. Niemi,et al.  Membrane transporters in drug development , 2010, Nature Reviews Drug Discovery.

[106]  Manuel Hidalgo,et al.  In vitro and In vivo Clinical Pharmacology of Dimethyl Benzoylphenylurea, a Novel Oral Tubulin-Interactive Agent , 2005, Clinical Cancer Research.

[107]  Yi Zhang,et al.  BCRP Transports Dipyridamole and is Inhibited by Calcium Channel Blockers , 2005, Pharmaceutical Research.

[108]  Jos H. Beijnen,et al.  P-Glycoprotein Limits Oral Availability, Brain Penetration, and Toxicity of an Anionic Drug, the Antibiotic Salinomycin , 2007, Antimicrobial Agents and Chemotherapy.

[109]  E. L. Volk,et al.  Wild-type breast cancer resistance protein (BCRP/ABCG2) is a methotrexate polyglutamate transporter. , 2003, Cancer research.

[110]  Robert W. Robey,et al.  Becatecarin (rebeccamycin analog, NSC 655649) is a transport substrate and induces expression of the ATP-binding cassette transporter, ABCG2, in lung carcinoma cells , 2009, Cancer Chemotherapy and Pharmacology.

[111]  K. Maeda,et al.  Involvement of BCRP (ABCG2) in the Biliary Excretion of Pitavastatin , 2005, Molecular Pharmacology.

[112]  Suneet Shukla,et al.  Modulation of the function of the multidrug resistance–linked ATP-binding cassette transporter ABCG2 by the cancer chemopreventive agent curcumin , 2006, Molecular Cancer Therapeutics.

[113]  Yoshihiko Ueda,et al.  The PI3K/Akt inhibitor LY294002 reverses BCRP-mediated drug resistance without affecting BCRP translocation. , 2012, Oncology reports.

[114]  T. Ishikawa,et al.  Transport of 7-ethyl-10-hydroxycamptothecin (SN-38) by breast cancer resistance protein ABCG2 in human lung cancer cells. , 2001, Biochemical and biophysical research communications.

[115]  Suzanne Skolnik,et al.  Attenuation of Intestinal Absorption by Major Efflux Transporters: Quantitative Tools and Strategies Using a Caco-2 Model , 2011, Drug Metabolism and Disposition.

[116]  BMC Bioinformatics , 2005 .

[117]  Bo Feng,et al.  Role of hepatic transporters in the disposition and hepatotoxicity of a HER2 tyrosine kinase inhibitor CP-724,714. , 2009, Toxicological sciences : an official journal of the Society of Toxicology.

[118]  Jing Li,et al.  Association of variant ABCG2 and the pharmacokinetics of epidermal growth factor receptor tyrosine kinase inhibitors in cancer patients , 2007, Cancer biology & therapy.

[119]  Mark N Milton,et al.  P-glycoprotein and breast cancer resistance protein affect disposition of tandutinib, a tyrosine kinase inhibitor. , 2010, Drug metabolism letters.

[120]  Suneet Shukla,et al.  Evidence for dual mode of action of a thiosemicarbazone, NSC73306: a potent substrate of the multidrug resistance–linked ABCG2 transporter , 2007, Molecular Cancer Therapeutics.

[121]  Alfred H. Schinkel,et al.  BREAST CANCER RESISTANCE PROTEIN (BCRP/ABCG2) TRANSPORTS FLUOROQUINOLONE ANTIBIOTICS AND AFFECTS THEIR ORAL AVAILABILITY, PHARMACOKINETICS, AND MILK SECRETION , 2006, Drug Metabolism and Disposition.

[122]  Yves Pommier,et al.  Novel E-ring camptothecin keto analogues (S38809 and S39625) are stable, potent, and selective topoisomerase I inhibitors without being substrates of drug efflux transporters , 2007, Molecular Cancer Therapeutics.

[123]  Marilyn E Morris,et al.  The sulfated conjugate of biochanin A is a substrate of breast cancer resistant protein (ABCG2). , 2011, Biopharmaceutics & drug disposition.

[124]  Takashi Usui,et al.  Utility of P-Glycoprotein and Organic Cation Transporter 1 Double-Transfected LLC-PK1 Cells for Studying the Interaction of YM155 Monobromide, Novel Small-Molecule Survivin Suppressant, with P-Glycoprotein , 2011, Drug Metabolism and Disposition.

[125]  Yuichi Sugiyama,et al.  Functional Involvement of Multidrug Resistance-Associated Protein 4 (MRP4/ABCC4) in the Renal Elimination of the Antiviral Drugs Adefovir and Tenofovir , 2007, Molecular Pharmacology.

[126]  Bo Feng,et al.  Role of Transporters in the Disposition of the Selective Phosphodiesterase-4 Inhibitor (+)-2-[4-({[2-(Benzo[1,3]dioxol-5-yloxy)-pyridine-3-carbonyl]-amino}-methyl)-3-fluoro-phenoxy]-propionic Acid in Rat and Human , 2007, Drug Metabolism and Disposition.

[127]  Jos H Beijnen,et al.  Brain accumulation of sunitinib is restricted by P‐glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) and can be enhanced by oral elacridar and sunitinib coadministration , 2012, International journal of cancer.

[128]  C. Paulusma,et al.  Oral Availability of Cefadroxil Depends on ABCC3 and ABCC4 , 2012, Drug Metabolism and Disposition.

[129]  A. Schinkel,et al.  Multidrug resistance and pharmacological protection mediated by the breast cancer resistance protein (BCRP/ABCG2). , 2002, Molecular cancer therapeutics.

[130]  Hui Zhang,et al.  A prediction model of substrates and non-substrates of breast cancer resistance protein (BCRP) developed by GA-CG-SVM method , 2011, Comput. Biol. Medicine.

[131]  N. Shaik,et al.  Substrate-Dependent Breast Cancer Resistance Protein (Bcrp1/Abcg2)-Mediated Interactions: Consideration of Multiple Binding Sites in in Vitro Assay Design , 2009, Drug Metabolism and Disposition.

[132]  J. Gasteiger,et al.  ITERATIVE PARTIAL EQUALIZATION OF ORBITAL ELECTRONEGATIVITY – A RAPID ACCESS TO ATOMIC CHARGES , 1980 .

[133]  Suneet Shukla,et al.  The calcium channel blockers, 1,4-dihydropyridines, are substrates of the multidrug resistance-linked ABC drug transporter, ABCG2. , 2006, Biochemistry.

[134]  Joe Palandra,et al.  Breast cancer resistance protein (ABCG2) and drug disposition: intestinal expression, polymorphisms and sulfasalazine as an in vivo probe , 2008, Pharmacogenetics and genomics.

[135]  S. Bates,et al.  ABCG2-mediated transport of photosensitizers: Potential impact on photodynamic therapy , 2005, Cancer biology & therapy.

[136]  A. V. van Herwaarden,et al.  The Breast Cancer Resistance Protein (BCRP/ABCG2) Affects Pharmacokinetics, Hepatobiliary Excretion, and Milk Secretion of the Antibiotic Nitrofurantoin , 2005, Molecular Pharmacology.

[137]  Teruko Imai,et al.  Evaluation of transport mechanism of prodrugs and parent drugs formed by intracellular metabolism in Caco-2 cells with modified carboxylesterase activity: temocapril as a model case. , 2011, Journal of pharmaceutical sciences.

[138]  M. J. van de Vijver,et al.  Subcellular localization and distribution of the breast cancer resistance protein transporter in normal human tissues. , 2001, Cancer research.

[139]  A. G. Blazquez,et al.  In vitro and in vivo interaction of moxidectin with BCRP/ABCG2. , 2009, Chemico-biological interactions.

[140]  S H Kaufmann,et al.  The HER tyrosine kinase inhibitor CI1033 enhances cytotoxicity of 7-ethyl-10-hydroxycamptothecin and topotecan by inhibiting breast cancer resistance protein-mediated drug efflux. , 2001, Cancer research.

[141]  R. Ford,et al.  The human breast cancer resistance protein (BCRP/ABCG2) shows conformational changes with mitoxantrone. , 2010, Structure.

[142]  Piet Borst,et al.  Intestinal Breast Cancer Resistance Protein (BCRP)/Bcrp1 and Multidrug Resistance Protein 3 (MRP3)/Mrp3 Are Involved in the Pharmacokinetics of Resveratrol , 2009, Molecular Pharmacology.

[143]  Takashi Tsuruo,et al.  Breast cancer resistance protein exports sulfated estrogens but not free estrogens. , 2003, Molecular pharmacology.

[144]  S. Bates,et al.  Transport of methotrexate, methotrexate polyglutamates, and 17beta-estradiol 17-(beta-D-glucuronide) by ABCG2: effects of acquired mutations at R482 on methotrexate transport. , 2003, Cancer research.

[145]  P. Neuvonen,et al.  ABCG2 Polymorphism Markedly Affects the Pharmacokinetics of Atorvastatin and Rosuvastatin , 2009, Clinical pharmacology and therapeutics.

[146]  Franciska Erdő,et al.  ABCG2 modulates chlorothiazide permeability--in vitro-characterization of its interactions. , 2012, Drug metabolism and pharmacokinetics.

[147]  E. Boerwinkle,et al.  Identification of a urate transporter, ABCG2, with a common functional polymorphism causing gout , 2009, Proceedings of the National Academy of Sciences.

[148]  Jos H Beijnen,et al.  The breast cancer resistance protein (Bcrp1/Abcg2) restricts exposure to the dietary carcinogen 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine. , 2003, Cancer research.

[149]  A. Calcagno,et al.  Role of the ABCG2 drug transporter in the resistance and oral bioavailability of a potent cyclin-dependent kinase/Aurora kinase inhibitor , 2006, Molecular Cancer Therapeutics.

[150]  Suneet Shukla,et al.  Identification of Compounds that Correlate with ABCG2 Transporter Function in the National Cancer Institute Anticancer Drug Screen , 2009, Molecular Pharmacology.

[151]  Sarah Spiegel,et al.  Estradiol Induces Export of Sphingosine 1-Phosphate from Breast Cancer Cells via ABCC1 and ABCG2* , 2010, The Journal of Biological Chemistry.

[152]  T. Litman,et al.  Functional analysis of candidate ABC transporter proteins for sitosterol transport. , 2002, Biochimica et biophysica acta.

[153]  Guoyu Pan,et al.  Abcg2/Bcrp1 Mediates the Polarized Transport of Antiretroviral Nucleosides Abacavir and Zidovudine , 2007, Drug Metabolism and Disposition.

[154]  Piet Borst,et al.  cGMP transport by vesicles from human and mouse erythrocytes , 2007, The FEBS journal.